These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16157829)

  • 41. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
    Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
    Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy.
    Oh JJ; Jeong SJ; Lee BK; Jeong CW; Byun SS; Hong SK; Lee SE
    BJU Int; 2013 Aug; 112(4):E265-71. PubMed ID: 23432960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biopsy of men with PSA level of 2.6 to 4.0 ng/mL associated with favorable pathologic features and PSA progression rate: a preliminary analysis.
    Zhu H; Roehl KA; Antenor JA; Catalona WJ
    Urology; 2005 Sep; 66(3):547-51. PubMed ID: 16140075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
    J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Annual PSA tests are not necessary for men with a PSA level below 2 ng/mL: findings of the Imari prostate cancer screening program.
    Uozumi J; Tokuda Y; Fujiyama C; Takagi N; Meiri H; Kuratomi K; Nakamura K; Ichigi Y; Yoshinaga H; Kinoshita N; Masaki Z
    Int J Urol; 2002 Jun; 9(6):334-9. PubMed ID: 12110098
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical significance of prostate specific antigen for early stage prostate cancer detection.
    Imai K; Ichinose Y; Kubota Y; Yamanaka H; Sato J; Saitoh M; Watanabe H; Ohe H
    Jpn J Clin Oncol; 1994 Jun; 24(3):160-5. PubMed ID: 7516445
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
    Ross KS; Carter HB; Pearson JD; Guess HA
    JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Family history and prostate cancer screening with prostate-specific antigen.
    Mäkinen T; Tammela TL; Stenman UH; Määttänen L; Rannikko S; Aro J; Juusela H; Hakama M; Auvinen A
    J Clin Oncol; 2002 Jun; 20(11):2658-63. PubMed ID: 12039927
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimal screening interval for men with low baseline prostate-specific antigen levels (≤1.0 ng/mL) in a prostate cancer screening program.
    Urata S; Kitagawa Y; Matsuyama S; Naito R; Yasuda K; Mizokami A; Namiki M
    World J Urol; 2017 Apr; 35(4):579-586. PubMed ID: 27421271
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland.
    Kwiatkowski M; Huber A; Stamm B; Lehmann K; Wernli M; Häfeli A; Recker F
    BJU Int; 2003 Dec; 92 Suppl 2():44-7. PubMed ID: 14983954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Distributions and characteristics of initial PSA and PSA velocity in Chinese men aged 50 years and younger without prostate cancer: a multi-center study.
    Yang W; Liu S; Hu C; Xie K; Wei X; Zeng W; Tang P
    J BUON; 2019; 24(2):832-837. PubMed ID: 31128043
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%.
    Ishidoya S; Ito A; Orikasa K; Kawamura S; Tochigi T; Kuwahara M; Yamanobe T; Tomita Y; Masumori N; Tsukamoto T; Shibuya D; Arai Y
    Jpn J Clin Oncol; 2008 Dec; 38(12):844-8. PubMed ID: 18941125
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Bristol prostate cancer pilot screening study--a 3-year follow-up.
    Brewster SF; Kemple T; MacIver AG; Astley JP; Gingell JC
    Br J Urol; 1994 Nov; 74(5):556-8. PubMed ID: 7530117
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting prostate cancer many years before diagnosis: how and why?
    Vickers AJ; Lilja H
    World J Urol; 2012 Apr; 30(2):131-5. PubMed ID: 22101902
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Serum prostate-specific antigen levels in older men with or at risk of HIV infection.
    Vianna LE; Lo Y; Klein RS
    HIV Med; 2006 Oct; 7(7):471-6. PubMed ID: 16925734
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population.
    Komatsu K; Wehner N; Prestigiacomo AF; Chen Z; Stamey TA
    Urology; 1996 Mar; 47(3):343-6. PubMed ID: 8633399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal prostate-specific antigen screening interval for prostate cancer.
    Kobayashi D; Takahashi O; Fukui T; Glasziou PP
    Ann Oncol; 2012 May; 23(5):1250-1253. PubMed ID: 21948815
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Four-year prostate-specific antigen progression in the non-cancer population of the European Randomized Study of Screening for Prostate Cancer.
    Páez A; Luján M; Raaijmakers R; Berenguer A;
    BJU Int; 2003 Dec; 92 Suppl 2():84-7. PubMed ID: 14983962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.